Ocular Hypertension Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Bausch + Lomb, Aerie Pharma, Santen Pharma, AbbVie (Allergan), Nicox, Kowa, Qlaris Bio, Noveome Bio

The Key Ocular Hypertension Companies in the market include - Bausch + Lomb, Alcon (Aerie Pharmaceuticals), Santen Pharmaceutical, AbbVie (Allergan), Nicox/Kowa, Qlaris Bio, Noveome Biotherapeutics, Visiox Pharma, Sun Pharma Advanced Research Company, JeniVision, Inc., Glaukos Corporation, D. Western Therapeutics Institute, Inc., AbbVie, TearClear Corp, Ocular Therapeutix, Inc., Perfuse Therapeutics, Inc., and others.

DelveInsight's "Ocular Hypertension Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Ocular Hypertension, historical and forecasted epidemiology as well as the Ocular Hypertension market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Ocular Hypertension market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Ocular Hypertension Market Forecast [https://www.delveinsight.com/sample-request/ocular-hypertension-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Ocular Hypertension Market Report:

*
The Ocular Hypertension market size is anticipated to grow with a significant CAGR of 3% during the study period (2020-2034).

*
In March 2025, SCIENTURE HOLDINGS, INC. announced that it has utilized its Equity Line of Credit (ELOC) to fund the commercial launch of Arbli Trademark (losartan potassium) Oral Suspension. The company also stated it will pause additional ELOC draws for the next 30 trading days or until its stock price hits $10 per share, whichever occurs first.

*
In February 2025, Qlaris Bio announced positive topline results from two randomized Phase II U.S. trials, Osprey and Apteryx, evaluating QLS-111 in patients with primary open-angle glaucoma (POAG) and ocular hypertension (OHT). Both masked trials successfully met all primary and secondary endpoints. The Osprey trial specifically assessed the therapy's tolerability, intraocular pressure (IOP)-lowering efficacy, and safety across multiple doses compared to a vehicle in 62 adult participants with POAG or OHT.

*
In November 2024, SpyGlass Pharma Trademark , a privately-owned ophthalmic biotechnology firm, has announced the completion of patient enrollment for its Phase I/II randomized, multi-center, controlled clinical trial (NCT06120842). This trial evaluates the SpyGlass Drug Delivery Platform in individuals with glaucoma or ocular hypertension. The platform is designed to provide long-term bimatoprost delivery, reducing intraocular pressure (IOP), and is implanted during standard cataract surgery.

*
In November 2024, MediPrint aims to advance two key programs in 2025. The first targets comfort enhancement in the daily disposable lens market using hyaluronic acid (HA). The second involves launching a Phase 3 clinical trial for LL-BMT1, designed to improve bioavailability, reduce side effects, and enhance patient convenience. LL-BMT1 has the potential to revolutionize the treatment of ocular hypertension and mild to moderate glaucoma.

*
The ocular hypertension market is expected to experience consistent growth, with a robust CAGR from 2024 to 2034. This expansion across the 7MM is fueled by the emergence of new treatments like NCX 470, QLS-111, and ST266, as well as an increasingly aging population.

*
DelveInsight's epidemiology model estimates that there were around 21 million prevalent cases of ocular hypertension across the 7MM in 2023, with 13 million diagnosed cases. These figures are expected to increase over the study period from 2020 to 2034.

*
In 2023, the United States reported the highest number of diagnosed ocular hypertension cases, totaling around 5.4 million.

*
In 2023, Germany had the highest number of diagnosed ocular hypertension cases among the EU4 and the UK, with around 1.3 million cases, followed by the UK with approximately 1.1 million cases. Spain had the lowest, reporting nearly 866 thousand cases.

*
In 2023, Japan reported approximately 2.7 million diagnosed cases of ocular hypertension, and this figure is anticipated to rise over the course of the study period.

*
Key Ocular Hypertension Companies: Bausch + Lomb, Alcon (Aerie Pharmaceuticals), Santen Pharmaceutical, AbbVie (Allergan), Nicox/Kowa, Qlaris Bio, Noveome Biotherapeutics, Laboratoires Thea, Rigshospitalet, Amneal Pharmaceuticals, Theratocular Biotek Co., Alcon Research, Otsuka Beijing Research Institute, Qlaris Bio, Inc., Nicox Ophthalmics, Ocuphire Pharma, Santen Inc., Ono Pharmaceutical, MediPrint Ophthalmics, Visiox Pharma, Sun Pharma Advanced Research Company, JeniVision, Inc., Glaukos Corporation, D. Western Therapeutics Institute, Inc., AbbVie, TearClear Corp, Ocular Therapeutix, Inc., Perfuse Therapeutics, Inc., and others

*
Key Ocular Hypertension Therapies: VYZULTA (latanoprostene bunod ophthalmic solution, RHOPRESSA, DURYSTA, NCX 470, QLS-111, ST266, T4090, Xalatan, Reference - LUMIGAN Registered , TO-O-1001, AR-17043, OPC-1085EL, QLS-111, NCX 470, Nyxol, Sepetaprost(DE-126/ONO-9054/STN1012600 ), LL-BMT1, PDP-716, V-GL1, NCX 470, Kinezodianone R hydrochloride, G2-TR intraocular implant containing travoprost, H-1337, AGN-193408 SR, Latanoprost ophthalmic solution, OTX-TIC, PER-001, and others

*
The Ocular Hypertension epidemiology based on gender analyzed that females are more affected than males

*
The Ocular Hypertension market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Ocular Hypertension pipeline products will significantly revolutionize the Ocular Hypertension market dynamics.

Ocular Hypertension Overview

Ocular hypertension refers to the condition where the pressure inside the eye, known as intraocular pressure (IOP), is higher than normal. This increased pressure can lead to potential damage to the optic nerve, which is crucial for vision. It's important to note that ocular hypertension doesn't always result in glaucoma, but it is considered a significant risk factor for the development of the condition.

Get a Free sample for the Ocular Hypertension Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/ocular-hypertension-market [https://www.delveinsight.com/report-store/ocular-hypertension-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Ocular Hypertension Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Ocular Hypertension Epidemiology Segmentation:

The Ocular Hypertension market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Ocular Hypertension

*
Prevalent Cases of Ocular Hypertension by severity

*
Gender-specific Prevalence of Ocular Hypertension

*
Diagnosed Cases of Episodic and Chronic Ocular Hypertension

Download the report to understand which factors are driving Ocular Hypertension epidemiology trends @ Ocular Hypertension Epidemiology Forecast [https://www.delveinsight.com/sample-request/ocular-hypertension-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Ocular Hypertension Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Ocular Hypertension market or expected to get launched during the study period. The analysis covers Ocular Hypertension market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Ocular Hypertension Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Ocular Hypertension Therapies and Key Companies

*
VYZULTA (latanoprostene bunod ophthalmic solution): Bausch + Lomb

*
RHOPRESSA: Alcon (Aerie Pharmaceuticals)/Santen Pharmaceutical

*
DURYSTA: AbbVie (Allergan)

*
NCX 470: Nicox/Kowa

*
QLS-111: Qlaris Bio

*
ST266: Noveome Biotherapeutics

*
T4090: Laboratoires Thea

*
Xalatan: Rigshospitalet

*
Reference - LUMIGAN Registered : Amneal Pharmaceuticals

*
TO-O-1001: Theratocular Biotek Co.

*
AR-17043: Alcon Research

*
OPC-1085EL: Otsuka Beijing Research Institute

*
QLS-111: Qlaris Bio, Inc.

*
NCX 470: Nicox Ophthalmics

*
Nyxol: Ocuphire Pharma

*
Sepetaprost(DE-126/ONO-9054/STN1012600 ): Santen Inc. /Ono Pharmaceutical

*
LL-BMT1: MediPrint Ophthalmics

*
PDP-716: Visiox Pharma/ Sun Pharma Advanced Research Company

*
JV-GL1: JeniVision, Inc.

*
NCX 470: Nicox Ophthalmics, Inc.

*
Kinezodianone R hydrochloride: Laboratoires Thea

*
G2-TR intraocular implant containing travoprost: Glaukos Corporation

*
H-1337: D. Western Therapeutics Institute, Inc.

*
AGN-193408 SR: AbbVie

*
Latanoprost ophthalmic solution: TearClear Corp

*
OTX-TIC: Ocular Therapeutix, Inc.

*
PER-001: Perfuse Therapeutics, Inc.

Discover more about therapies set to grab major Ocular Hypertension market share @ Ocular Hypertension Treatment Landscape [https://www.delveinsight.com/sample-request/ocular-hypertension-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Scope of the Ocular Hypertension Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Ocular Hypertension Companies: Bausch + Lomb, Alcon (Aerie Pharmaceuticals)/Santen Pharmaceutical, AbbVie (Allergan), Nicox/Kowa, Qlaris Bio, Noveome Biotherapeutics, Laboratoires Thea, Rigshospitalet, Amneal Pharmaceuticals, Theratocular Biotek Co., Alcon Research, Otsuka Beijing Research Institute, Qlaris Bio, Inc., Nicox Ophthalmics, Ocuphire Pharma, Santen Inc., Ono Pharmaceutical, MediPrint Ophthalmics, Visiox Pharma, Sun Pharma Advanced Research Company, JeniVision, Inc., Glaukos Corporation, D. Western Therapeutics Institute, Inc., AbbVie, TearClear Corp, Ocular Therapeutix, Inc., Perfuse Therapeutics, Inc., and others

*
Key Ocular Hypertension Therapies: VYZULTA (latanoprostene bunod ophthalmic solution, RHOPRESSA, DURYSTA, NCX 470, QLS-111, ST266, T4090, Xalatan, Reference - LUMIGAN Registered , TO-O-1001, AR-17043, OPC-1085EL, QLS-111, NCX 470, Nyxol, Sepetaprost(DE-126/ONO-9054/STN1012600 ), LL-BMT1, PDP-716, V-GL1, NCX 470, Kinezodianone R hydrochloride, G2-TR intraocular implant containing travoprost, H-1337, AGN-193408 SR, Latanoprost ophthalmic solution, OTX-TIC, PER-001, and others

*
Ocular Hypertension Therapeutic Assessment: Ocular Hypertension current marketed and Ocular Hypertension emerging therapies

*
Ocular Hypertension Market Dynamics: Ocular Hypertension market drivers and Ocular Hypertension market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Ocular Hypertension Unmet Needs, KOL's views, Analyst's views, Ocular Hypertension Market Access and Reimbursement

To know more about Ocular Hypertension companies working in the treatment market, visit @ Ocular Hypertension Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/ocular-hypertension-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Ocular Hypertension Market Report Introduction

2. Executive Summary for Ocular Hypertension

3. SWOT analysis of Ocular Hypertension

4. Ocular Hypertension Patient Share (%) Overview at a Glance

5. Ocular Hypertension Market Overview at a Glance

6. Ocular Hypertension Disease Background and Overview

7. Ocular Hypertension Epidemiology and Patient Population

8. Country-Specific Patient Population of Ocular Hypertension

9. Ocular Hypertension Current Treatment and Medical Practices

10. Ocular Hypertension Unmet Needs

11. Ocular Hypertension Emerging Therapies

12. Ocular Hypertension Market Outlook

13. Country-Wise Ocular Hypertension Market Analysis (2020-2034)

14. Ocular Hypertension Market Access and Reimbursement of Therapies

15. Ocular Hypertension Market Drivers

16. Ocular Hypertension Market Barriers

17. Ocular Hypertension Appendix

18. Ocular Hypertension Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=ocular-hypertension-market-positioned-for-accelerated-development-through-2034-delveinsight-finds-bausch-lomb-aerie-pharma-santen-pharma-abbvie-allergan-nicox-kowa-qlaris-bio-noveome-bio]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.